|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn's disease and rheumatoid arthritis: Results of a systematic review显示文摘AIM:To investigate adherence rates in tumor necrosis factor-α (TNF-α)-inhibitors in Crohn's disease (CD) and rheumatoid arthritis (RA) by systematic review of medical literature. METHODS:A structured search of PubMed between 2001 and 2011 was conducted to identify publications that assessed treatment with TNF-α inhibitors providing data about adherence in CD and RA. Therapeutic agents of interest where adalimumab, infliximab and etanercept, since these are most commonly used for both diseases. Studies assessing only drug survival or continuation rates were excluded. Data describing adherence with TNF-α inhibitors were extracted for each selected study. Given the large variation between definitions of measurement of adherence, the definitions as used by the authors where used in our calculations. Data were tabulated and also presented descriptively. Sample size-weighted pooled proportions of patients adherent to therapy and their 95%CI were calculated.To compare adherence between infliximab, adalimumab and etanercept, the adherence rates where graphed alongside two axes. Possible determinants of adherence were extracted from the selected studies and tabulated using the presented OR. RESULTS:Three studies on CD and three on RA were identified, involving a total of 8147 patients (953 CD and 7194 RA). We identified considerable variation in the definitions and methodologies of measuring adherence between studies. The calculated overall sample size-weighted pooled proportion for adherence to TNF-α inhibitors in CD was 70% (95%CI:67%-73%) and 59% in RA (95%CI:58%-60%). In CD the adherence rate for infliximab (72%) was highercompared to adalimumab (55%), with a relative risk of 1.61 (95%CI:1.27-2.03), whereas in RA adherence for adalimumab (67%) was higher compared to both infliximab (48%) and etanercept (59%), with a relative risk of 1.41 (95%CI:1.3-1.52) and 1.13 (95%CI:1.10-1.18) respectively. In comparative studies in RA adherence to infliximab was better than etanercept and etanercept did better than adalimumab. In three studies, the most consistent factor associated with lower adherence was female gender. Results for age, immunomodulator use and prior TNF-α inhibitors use were conflicting. CONCLUSION:One-third of both CD and RA patients treated with TNF-α inhibitors are non-adherent. Female gender was consistently identified as a negative determinant of adherence. | Herma H Fidder Maartje MJ Singendonk Mike van der Have Bas Oldenburg Martijn GH van Oijen | 2013 | World Journal of Gastroenterology2013，19，27： | 2 |
| 2 | Levels of C-reactive Protein Are Associated With Response to Infliximab Therapy in Patients With Crohn’s Disease显示文摘 | Matthias Jürgens Jestinah M. Mahachie John Isabelle Cleynen Fabian Schnitzler Herma Fidder Wouter van Moerkercke Vera Ballet Maja Noman Ilse Hoffman Gert van Assche Paul J. Rutgeerts Kristel van Steen Severine Vermeire | 2011 | Clinical Gastroenterology and Hepatology2011，，5： | 2 |
| 3 | Cerebral magnetic resonance imaging in quiescent Crohn's disease patients with fatigue显示文摘AIM To evaluate brain involvement in quiescent Crohn's disease (CD) patients with fatigue using quantitative magnetic resonance imaging(MRI).METHODS Multiple MRI techniques were used to assess cerebral changes in 20 quiescent CD patients with fatigue(defined with at least 6 points out of an 11-point numeric rating scale compared with 17 healthy age and gender matched controls without fatigue. Furthermore, mental status was assessed by cognitive functioning, based on the neuropsychological inventory including the different domains global cognitive functioning, memory and executive functioning and in addition mood and quality of life scores. Cognitive functioning and mood status were correlated with MRI findings in the both study groups.RESULTS Reduced glutamate + glutamine (Glx = Glu + Gln) concentrations (P = 0.02) and ratios to total creatine(P = 0.02) were found in CD patients compared with controls. Significant increased Cerebral Blood Flow(P = 0.05) was found in CD patients (53.08 ± 6.14 mL/100 g/min) compared with controls (47.60 ± 8.62 mL/100 g/min). CD patients encountered significantly more depressive symptoms (P < 0.001). Cognitive functioning scores related to memory (P = 0.007) and executive functioning (P = 0.02) were lower in CD patients and both scores showed correlation with depression and anxiety. No correlation was found subcortical volumes between CD patients and controls in the T1-weighted analysis. In addition, no correlation was found between mental status and MRI findings.CONCLUSION This work shows evidence for perfusion, neurochemical and mental differences in the brain of CD patients with fatigue compared with healthy controls. | Sanne van Erp Ece Ercan Perla Breedveld Lianne Brakenhoff Eidrees Ghariq Sophie Schmid Matthias van Osch Mark van Buchem Bart Emmer Jeroen van der Grond Ron Wolterbeek Daniel Hommes Herma Fidder Nic van der Wee Tom Huizinga Désirée van der Heijde Huub Middelkoop Itamar Ronen Andrea van der Meulen-de Jong | 2017 | World Journal of Gastroenterology2017，23，6： | 2 |
| 4 | The Bsm I vitamin 0 receptor gene polymorphism is associated with ulcerative colitis inJewish Ashkenazi patients显示文摘 | Dresner PR Ackerman Z Eliakim R Karban A Chewers Y Fidder HH | 2004 | Genet Test2004，8，4： | 1 |
| 5 | Inhibition of vascular endothelial growth factor(VEGF)-induced endothelial cell proliferation by a peptide corresponding to the exon 7-encoded domain of VEGF165 显示文摘 | Soker S Gollamudi-Payne S Fidder H | 1997 | J Biol Chem1997，272，31： | 1 |
| 6 | Retrospective detection of exposure to organophosphorus anti-cholinesterases:mass spectrometric analysis of phosphylated human butyrylcholinesterase 显示文摘 | Fidder A Hulst AG Noort D | 2002 | Chem Res Toxicol2002，15，4： | 1 |
| 7 | Clinical and demographic characterization of Jewish Crohn's disease patients in Israel显示文摘 | AVIDAN B LAHAV M | 2003 | J Clin Gastroenterol2003，36，1： | 1 |
| 8 | Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain显示文摘 | Soker S Fidder H Neufeld G | 1996 | J Biol Chem1996，271，10： | 1 |
| 9 | Inhibition of vascular endothelial growth factor(VEGF)-induced endothelial cell proliferation by a peptide corresponding to the exon 7-encoded domain of VEGF165 显示文摘 | Soker S Gollamudi-Payne S Fidder H | 1997 | J Biol Chem1997，272，31： | 1 |
| 10 | Origin and biology of cancer metastasis显示文摘 | Fidder IJ | 1989 | Cytometry1989，10，： | 1 |
| 11 | Preliminary clinical studies with thromboxane synthase inhibitors and thromboxane receptors blockers显示文摘 | Fidder GI Lumley P | 1990 | Circulation1990，81，1： | 1 |
| 12 | Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial cell proliferation by a peptide corresponding to the exon 7-encoded domain of VEGF165 显示文摘 | Soker S Gollamudi-Payne S Fidder H | 1997 | J Biol Chem1997，272，31： | 1 |
| 13 | Retrospective detection of exposure to organo-phosphorus anti-choline sterases: Mass spectro metric analysis of phosphylated human butyryl- cholinesterase显示文摘 | FIDDER A NOORT D HULST A G | 2002 | Chem Res Toxicol2002，15，4： | 1 |
| 14 | Somatostatin inhibits pro-inflammatory cytokine secretion from rat hepatic stellate cells显示文摘 | Lang A Sakhnini E Fidder HH | 2005 | Liver Int2005，25，4： | 1 |
| 15 | Verification of exposure to organophos- phates: Generic mass spectrometric method for detection of human butyrylcholinesterase adducts 显示文摘 | NOORT D FIDDER A van der SCHANS M J | 2006 | AnalChem2006，78，18： | 1 |
| 16 | 查看详情显示文摘 | Greve C Preketes N. K Fidder H Costard R. Koeppe B. Heisler I.A. Mukamel S. Temps F. Nibbering E.T.J. Elsaes-ser T | | 0，，： | 1 |
| 17 | Long - term outcome of treatment with infliximab in 614 patients with Crohn' s disease : resuits from a singlecentre cohort 显示文摘 | Schnitzler F Fidder M Ferante M | 2009 | Gut2009，58，4： | 1 |
| 18 | Long - term safety of inflix- imab for the treatment of Crohn' s disease : a single - centre cohort study显示文摘 | Fidder M Schnitzler F Ferante M | 2009 | Gut2009，58，4： | 1 |
| 19 | The joint–gut axis in inflammatory bowel diseases显示文摘 | Lianne K.P.M. Brakenhoff Désirée M. van der Heijde Daniel W. Hommes Tom W.J. Huizinga Herma H. Fidder | 2009 | Journal of Crohn’s and Colitis2009，，3： | 1 |
| 20 | Budesonide foam vs hydrocortisone acetate foam in the treatment of active ulcerative proctcsigmoiditis 显示文摘 | Bar-Meir S Fidder HH Faszczyk M | 2003 | Dis Colon Rectum2003，46，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员